Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,163,032
  • Shares Outstanding, K 2,532,900
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.55
  • Price/Sales 4.42
  • Price/Cash Flow 11.75
  • Price/Book 7.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.76
  • Number of Estimates 3
  • High Estimate 0.85
  • Low Estimate 0.71
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -41.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.12 +2.70%
on 12/07/18
41.41 -5.46%
on 11/15/18
-2.25 (-5.43%)
since 11/14/18
3-Month
36.67 +6.78%
on 10/25/18
41.78 -6.28%
on 11/13/18
+1.70 (+4.54%)
since 09/14/18
52-Week
32.69 +19.76%
on 03/01/18
41.78 -6.28%
on 11/13/18
+5.86 (+17.60%)
since 12/14/17

Most Recent Stories

More News
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

AZN : 39.15 (-0.23%)
JNJ : 133.00 (-10.04%)
LLY : 111.93 (-2.55%)
NVS : 87.39 (-1.14%)
RHHBY : 31.0900 (-2.54%)
PFE : 43.80 (-1.73%)
BMY : 52.12 (-2.83%)
Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi

FDA grants breakthrough device designation to GuardantOMNI test used

GH : 39.81 (-4.97%)
AZN : 39.15 (-0.23%)
Novartis Presents Additional Data on Breast Cancer Candidate

Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.

AZN : 39.15 (-0.23%)
MRK : 76.48 (-3.20%)
NVS : 87.39 (-1.14%)
BMY : 52.12 (-2.83%)
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study

AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.

AZN : 39.15 (-0.23%)
MRK : 76.48 (-3.20%)
INCY : 66.25 (-1.55%)
BMY : 52.12 (-2.83%)
Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies

The FDA is committed to doing what is can to stimulate the development of more products by improving the consistency and efficiency fueling biotech and pharma companies in the pharmaceutical industry forge...

OGEN : 0.94 (+1.08%)
AZN : 39.15 (-0.23%)
CLVS : 20.76 (-4.02%)
NVLN : 1.10 (+4.76%)
MBRX : 1.26 (unch)
Inovio (INO) to Receive Milestone Payment From AstraZeneca

Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.

AZN : 39.15 (-0.23%)
INO : 4.86 (-4.71%)
VNDA : 26.24 (+0.34%)
ALXN : 109.43 (-2.67%)
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

Glaxo (GSK) announces definitive deal to buy TESARO.

AZN : 39.15 (-0.23%)
CLVS : 20.76 (-4.02%)
TSRO : 73.69 (-1.07%)
GSK : 37.61 (-0.87%)
TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer

TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt....

AZN : 39.15 (-0.23%)
CLVS : 20.76 (-4.02%)
TSRO : 73.69 (-1.07%)
GSK : 37.61 (-0.87%)
New Long-Term Data on CALQUENCE Presented at ASH 2018

--97% overall response rate in treatment-naive chronic lymphocytic leukemia trial population at three and a half years

AZN : 39.15 (-0.23%)
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease

AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.

AZN : 39.15 (-0.23%)
MRK : 76.48 (-3.20%)
TEVA : 18.46 (-2.94%)
GSK : 37.61 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 39.39
1st Resistance Point 39.27
Last Price 39.15
1st Support Level 38.97
2nd Support Level 38.79

See More

52-Week High 41.78
Last Price 39.15
Fibonacci 61.8% 38.30
Fibonacci 50% 37.23
Fibonacci 38.2% 36.16
52-Week Low 32.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar